The heme and radical scavenger α


Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
07 Jun 2019
Historique:
received: 27 11 2018
accepted: 25 04 2019
entrez: 9 6 2019
pubmed: 9 6 2019
medline: 14 1 2020
Statut: epublish

Résumé

Germinal matrix intraventricular hemorrhage (GM-IVH) is associated with cerebro-cerebellar damage in very preterm infants, leading to neurodevelopmental impairment. Penetration, from the intraventricular space, of extravasated red blood cells and extracellular hemoglobin (Hb), to the periventricular parenchyma and the cerebellum has been shown to be causal in the development of brain injury following GM-IVH. Furthermore, the damage has been described to be associated with the cytotoxic nature of extracellular Hb-metabolites. To date, there is no therapy available to prevent infants from developing either hydrocephalus or serious neurological disability. Mechanisms previously described to cause brain damage following GM-IVH, i.e., oxidative stress and Hb-metabolite toxicity, suggest that the free radical and heme scavenger α Using a preterm rabbit pup model of IVH, where IVH was induced shortly after birth in pups delivered by cesarean section at E29 (3 days prior to term), we investigated the brain distribution of recombinant A1M (rA1M) following intracerebroventricular (i.c.v.) administration at 24 h post-IVH induction. Further, short-term functional protection of i.c.v.-administered human A1M (hA1M) following IVH in the preterm rabbit pup model was evaluated. Following i.c.v. administration, rA1M was distributed in periventricular white matter regions, throughout the fore- and midbrain and extending to the cerebellum. The regional distribution of rA1M was accompanied by a high co-existence of positive staining for extracellular Hb. Administration of i.c.v.-injected hA1M was associated with decreased structural tissue and mitochondrial damage and with reduced mRNA expression for proinflammatory and inflammatory signaling-related genes induced by IVH in periventricular brain tissue. The results of this study indicate that rA1M/hA1M is a potential candidate for neuroprotective treatment following preterm IVH.

Sections du résumé

BACKGROUND BACKGROUND
Germinal matrix intraventricular hemorrhage (GM-IVH) is associated with cerebro-cerebellar damage in very preterm infants, leading to neurodevelopmental impairment. Penetration, from the intraventricular space, of extravasated red blood cells and extracellular hemoglobin (Hb), to the periventricular parenchyma and the cerebellum has been shown to be causal in the development of brain injury following GM-IVH. Furthermore, the damage has been described to be associated with the cytotoxic nature of extracellular Hb-metabolites. To date, there is no therapy available to prevent infants from developing either hydrocephalus or serious neurological disability. Mechanisms previously described to cause brain damage following GM-IVH, i.e., oxidative stress and Hb-metabolite toxicity, suggest that the free radical and heme scavenger α
METHODS METHODS
Using a preterm rabbit pup model of IVH, where IVH was induced shortly after birth in pups delivered by cesarean section at E29 (3 days prior to term), we investigated the brain distribution of recombinant A1M (rA1M) following intracerebroventricular (i.c.v.) administration at 24 h post-IVH induction. Further, short-term functional protection of i.c.v.-administered human A1M (hA1M) following IVH in the preterm rabbit pup model was evaluated.
RESULTS RESULTS
Following i.c.v. administration, rA1M was distributed in periventricular white matter regions, throughout the fore- and midbrain and extending to the cerebellum. The regional distribution of rA1M was accompanied by a high co-existence of positive staining for extracellular Hb. Administration of i.c.v.-injected hA1M was associated with decreased structural tissue and mitochondrial damage and with reduced mRNA expression for proinflammatory and inflammatory signaling-related genes induced by IVH in periventricular brain tissue.
CONCLUSIONS CONCLUSIONS
The results of this study indicate that rA1M/hA1M is a potential candidate for neuroprotective treatment following preterm IVH.

Identifiants

pubmed: 31174551
doi: 10.1186/s12974-019-1486-4
pii: 10.1186/s12974-019-1486-4
pmc: PMC6554963
doi:

Substances chimiques

Alpha-Globulins 0
Free Radical Scavengers 0
alpha-1-microglobulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122

Références

Blood. 2001 Sep 15;98(6):1802-11
pubmed: 11535514
Blood. 2002 Mar 15;99(6):1894-901
pubmed: 11877257
Pediatrics. 2002 Jul;110(1 Pt 1):143-51
pubmed: 12093960
J Neurosci. 2002 Nov 15;22(22):9821-30
pubmed: 12427838
Front Biosci. 2003 Jan 01;8:d357-9
pubmed: 12456301
Curr Med Chem. 2003 Oct;10(20):2185-96
pubmed: 12871092
Neurology. 1992 Sep;42(9):1717-23
pubmed: 1513459
J Pediatr. 2004 Nov;145(5):593-9
pubmed: 15520756
Free Radic Biol Med. 2005 Mar 1;38(5):557-67
pubmed: 15683711
Pediatrics. 2005 Apr;115(4):997-1003
pubmed: 15805376
Toxicol Lett. 2005 Jul 4;157(3):175-88
pubmed: 15917143
Ann Neurol. 2005 Jul;58(1):108-20
pubmed: 15984031
Nat Rev Mol Cell Biol. 2005 Oct;6(10):789-800
pubmed: 16314868
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8263-8
pubmed: 16702549
Am J Hematol. 2007 Feb;82(2):134-44
pubmed: 16986127
Prog Neurobiol. 2006 Oct;80(3):129-64
pubmed: 17029752
Protein Expr Purif. 2007 May;53(1):145-52
pubmed: 17169572
J Int Neuropsychol Soc. 2007 Jul;13(4):571-81
pubmed: 17521479
J Biol Chem. 2007 Oct 26;282(43):31493-503
pubmed: 17766242
Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F153-61
pubmed: 18296574
Acta Neuropathol. 2008 Oct;116(4):371-82
pubmed: 18696091
Pediatrics. 2009 Mar;123(3):1037-44
pubmed: 19255037
J Comput Assist Tomogr. 1991 Nov-Dec;15(6):923-9
pubmed: 1939769
Neuroimage. 2009 Oct 1;47(4):1487-95
pubmed: 19450693
JAMA. 2009 Jun 3;301(21):2225-33
pubmed: 19491184
J Matern Fetal Neonatal Med. 2009 Jun;22(6):491-500
pubmed: 19504405
J Dev Behav Pediatr. 2010 May;31(4):286-94
pubmed: 20431402
Brain. 2010 Aug;133(Pt 8):2264-80
pubmed: 20488889
Pediatrics. 2010 Sep;126(3):443-56
pubmed: 20732945
Stroke. 2011 Feb;42(2):465-70
pubmed: 21164132
Arch Gen Psychiatry. 2011 Jul;68(7):742-52
pubmed: 21727256
Ultrasound Med Biol. 2012 Mar;38(3):423-31
pubmed: 22305058
Antioxid Redox Signal. 2013 Jun 1;18(16):2017-28
pubmed: 23157686
DNA Cell Biol. 2013 Feb;32(2):36-40
pubmed: 23249270
Arch Dis Child Fetal Neonatal Ed. 2013 Jul;98(4):F291-7
pubmed: 23258839
Magn Reson Med. 1990 May;14(2):330-46
pubmed: 2345513
Pediatrics. 2013 Jul;132(1):62-71
pubmed: 23733804
J Neuroinflammation. 2013 Aug 06;10:100
pubmed: 23915174
PLoS One. 2014 Jan 28;9(1):e86353
pubmed: 24489717
Clin Perinatol. 2014 Mar;41(1):47-67
pubmed: 24524446
Ann Neurol. 2014 Jun;75(6):876-89
pubmed: 24752976
Blood. 2014 Jun 12;123(24):3689-90
pubmed: 24926069
Free Radic Biol Med. 2014 Sep;74:274-82
pubmed: 25035076
Neurosurgery. 2014 Dec;75(6):696-705; discussion 706
pubmed: 25121790
Pediatr Neonatol. 2015 Feb;56(1):46-52
pubmed: 25154794
J Neuroinflammation. 2014 Dec 02;11:200
pubmed: 25441622
Brain Res. 2015 Jan 12;1594:115-24
pubmed: 25451129
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753
J Pediatr. 2016 Jan;168:41-9.e1
pubmed: 26526364
J Korean Med Sci. 2015 Oct;30 Suppl 1:S52-8
pubmed: 26566358
Pediatrics. 2015 Dec;136(6):1132-43
pubmed: 26598455
Brain Res. 2016 Mar 15;1635:86-94
pubmed: 26772987
Pediatrics. 1989 Nov;84(5):797-801
pubmed: 2677959
J Neuroinflammation. 2016 Feb 01;13:26
pubmed: 26831741
Oxid Med Cell Longev. 2016;2016:1203285
pubmed: 27190572
Front Physiol. 2016 Aug 03;7:330
pubmed: 27536248
Drug Discov Today. 2017 Apr;22(4):736-743
pubmed: 27988357
Transl Stroke Res. 2017 Jun 10;:null
pubmed: 28601919
Blood Coagul Fibrinolysis. 2018 Jan;29(1):25-29
pubmed: 28901997
Early Hum Dev. 2018 Jan;116:1-8
pubmed: 29091782
Antioxid Redox Signal. 2019 Feb 1;30(4):489-504
pubmed: 29471681
J Pediatr. 2018 Sep;200:24-29.e3
pubmed: 29754865
Antioxid Redox Signal. 2019 May 10;30(14):1746-1759
pubmed: 29943622
J Microsc. 1986 Aug;143(Pt 2):125-37
pubmed: 3531523
J Cell Biol. 1970 Mar;44(3):655-66
pubmed: 4190069
J Biol Chem. 1968 Feb 10;243(3):465-75
pubmed: 4966113
J Clin Pathol. 1980 Aug;33(8):786-91
pubmed: 6159369
Eur Neurol. 1983;22(1):1-6
pubmed: 6188615
J Histochem Cytochem. 1995 Feb;43(2):115-23
pubmed: 7529784
Pediatr Neurol. 1995 Oct;13(3):230-4
pubmed: 8554660
Annu Rev Cell Dev Biol. 1997;13:425-56
pubmed: 9442880

Auteurs

Olga Romantsik (O)

Pediatrics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Alex Adusei Agyemang (AA)

Pediatrics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Snjolaug Sveinsdóttir (S)

Pediatrics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Sigurbjörg Rutardóttir (S)

Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Bo Holmqvist (B)

ImaGene-iT AB, Medicon Village, Lund, Sweden.

Magnus Cinthio (M)

Department of Electrical Measurements, Lund University, Lund, Sweden.

Mattias Mörgelin (M)

Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Gulcin Gumus (G)

Fetal i+D Fetal Medicine Research Center, BCNatal Barcelona Center for Maternal-Fetal and Neonatal Medicine, University of Barcelona, Barcelona, Spain.

Helena Karlsson (H)

A1M Pharma AB, Lund, Sweden.

Stefan R Hansson (SR)

Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Bo Åkerström (B)

Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

David Ley (D)

Pediatrics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Magnus Gram (M)

Pediatrics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. magnus.gram@med.lu.se.
Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. magnus.gram@med.lu.se.
A1M Pharma AB, Lund, Sweden. magnus.gram@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH